11th Annual Managed Markets and Account Management Strategies Conference

September 18-19, 2019 | New Orleans, LA

Doubletree by Hilton New Orleans Hotel

Download AgendaRegister Now

DAY ONE | WEDNESDAY, SEPTEMBER 18

8:00 REGISTRATION & WELCOME COFFEE

8:50 OPENING REMARKS

9:00 OPENING ICE BREAKER: MANAGED MARKETS MANAGEMENT FOR EXECUTIVE LEVEL AUDIENCE
This interactive ice breaker will open the event with an opportunity for all participants to move around the conference room with the goal of meeting other delegates and engaging in swift discussions. The audience is encouraged to briefly exchange perspectives on the daily challenges of executive level audiences, discussing challenges associated with the evolution of the managed markets role, potential elimination of rebates and payer engagement best practices. Furthermore, participants in this warm-up session are also given the opportunity to directly build contacts.

 

9:30 KEYNOTE LEGAL PERSPECTIVE: THE DRUG PRICING LANDSCAPE – A SURVEY OF CURRENT AND FUTURE LEGAL AND REGULATORY REFORMS
While the Trump Administration withdrew its much-discussed proposed rule removing safe harbor protection for rebates in July, drug pricing reform is still front-and-center in both the Administration and Congress. A number of pending and likely new proposals from the Administration – including recent reforms to the Part D program, an anticipated International Pricing Index model, and drug re-importation – could have major impacts on the coverage and reimbursement of pharmaceutical products. So, too, Congress continues to weigh its options in the drug pricing debate – and rebate reform is not off the table. This session provides an important update on current, proposed, and expected changes affecting pharmaceutical pricing and reimbursement.

Ross Margulies, FOLEY HOAG LLP

 

10:15 COFFEE AND NETWORKING BREAK

 

10:45 PANEL: HEALTHCARE DELIVERY & PATIENT ADHERENCE TRENDS EFFECTS ON MANAGED CARE

  • Deciphering influences on healthcare prescribing practices
  • Evolution of smart and digital healthcare initiatives in care delivery
  • Impact of adherence management on managed care decisions
  • Shift in care models effect on overall industry drug spend

Susan Poretta, HORIZON BCBSNJ

Mary Ellen Benzik, ICARE, INDEPENDENT CARE HEALTH PLAN

Dana Fletcher, Senior Director, Pharmaceutical Trade Relations, PRIME THERAPEUTICS

 

11:30 LECTURE: ANALYZING THE LEGAL ISSUES IN PRIOR AUTHORIZATION

  • Benchmarks for establishing prior authorization needs
  • Status of real-time verification processes
  • Impact of PAs on prescribing and drug spend
  • Benefits & risks of prior authorization digitization

William Sarraille, SIDLEY AUSTIN

 

12:15 LUNCHEON FOR ALL SPEAKERS, SPONSORS AND ATTENDEES

TRACKED BOARDROOM STYLE SESSIONS

TRACK ONE

1:30 SHOWCASING PRODUCT QUALITIES THROUGH VALUE PROPOSITION ENHANCEMENT

  • Data requirements for product dossiers
    • Clinical information
    • Non-clinical support
  • Strategies for tailoring value propositions
  • Inclusion of data based on regional needs

Ray Frost, MELINTA THERAPEUTICS

 

2:15 PRE-LAUNCH CONSIDERATIONS: PROACTIVELY COMMUNICATING PRODUCT VALUE

  • Timeline for communication with payers for upcoming products
  • Key stakeholders to involve in payer dossier development
  • Compilation of necessary data for product dossiers
  • Involvement of MSLs in early payer conversations

Juan Trippe, INDIVIOR

TRACK TWO

1:30 PAYER NEGOTIATION FOR LEGACY THERAPIES VS. NEW PRODUCTS

  • Difference in data expectations from payers
  • Impact of clinical vs. real world evidence
  • Communication strategy for legacy vs. new products

Sean Quinn, HIGHMARK

 

2:15 EXAMINING TRANSPARENCY INITIATIVES SURROUNDING DRUG PRICING

  • Direct-to-consumer ad drug pricing transparency rule
  • New & proposed state & government pricing legislation
  • Pricing transparency effect on product commercialization

Danielle Davis, GILEAD SCIENCES

3:00 COFFEE AND NETWORKING BREAK

3:30 UTILIZING EFFECTIVE ENGAGEMENT TACTICS FOR REGIONAL CUSTOMERS

  • Benefits of strong regional customer engagement
  • Tailoring communication based on regional market needs
  • Leveraging national contacts to connect with regional leaders

Terry Ahlers, BAYER

 

4:15 RECOGNIZING THE IMPORTANCE FOR INCREASED ENGAGEMENT WITH IDN STAKEHOLDERS

  • Building support of product access within IDN networks
  • Strategies employed by IDNs to stabilize costs & impact on access
    • Prescribing standardization
    • Outcomes tracking
  • Understanding the changes in IDN and PBM relationships

Josh Rich, KALA PHARMACEUTICALS

3:30 POSITIONING PRODUCTS TO AVOID PLACEMENT ON EXCLUSION LISTS

  • Healthcare delivery trends that impact exclusion decisions
  • Economic factors of therapeutic areas most often on exclusions
  • Opportunities for removing product’s from exclusionary lists
  • Influence exclusion list have had on healthcare spending

Ross Margulies, Senior Associate, FOLEY HOAG LLP

 

4:15 THERAPEUTIC SPOTLIGHT: MARKET INFLUENCES FOR RARE DISEASE COVERAGE

  • Challenges in price forecasting for rare disease products
  • Strategies to ensure uninterrupted patient access in rare disease
  • Reviewing trends in prescribing practices of rare disease therapies

5:00 COCKTAIL RECEPTION SPONSORED BY Q1 PRODUCTIONS